The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
An upcoming DCAT webinar this coming Tuesday Jan. 26, will provide thought leadership on what pharma companies, CDMOs/CMOs and other suppliers need to consider to further mitigate supply risk post COVID-19.
The COVID-19 pandemic has placed new...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from Pfizer, AstraZeneca, Lilly, Sinovac, Grifols, and Abbott.
Manufacturing and supply of COVID-19 vaccines and drugs
Pfizer, BioNTech Provide Mfg, Delivery...
The European Commission (EC) is calling on its 27 member states to accelerate the rollout of COVID-19 vaccinations across the European Union (EU) with targets set for March 2021 and the summer of 2021.
In a communication document issued...
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, and Merus, a Utrecht, The Netherlands-based clinical-stage oncology company developing multi-specific antibodies, have announced a research collaboration and...
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, Moderna, J&J, GSK, Novavax, Alexion, CureVac, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
EU In Talks to Purchase More Doses of...
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, has announced that the US government has agreed to purchase additional supply of its antibody cocktail (consisting of casirivimab and imdevimab) for treating...
Sanofi has agreed to acquire Kymab, a Cambridge, UK-based biopharmaceutical company, in a $1.45-billion deal ($1.1 billion upfront and up to $350 million in milestones).
Kymab’s lead product is KY1005, in Phase IIa development, for treating atopic...
Sanofi has chosen the name EUROAPI for its new European company dedicated to the development, production and marketing of active pharmaceutical ingredients (APIs).
Sanofi announced the formation of the standalone company in February 2020. The new...
Novartis has signed a strategic collaboration agreement to in-license from BeiGene, a Beijing-based pharmaceutical company, in major markets outside of China, tislelizumab, a drug for treating classical Hodgkin’s lymphoma and metastatic urothelial...
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, has filed a lawsuit against the US government for a recently issued drug-pricing rule that uses a Most Favored Nation (MFN) drug-payment model that would set the...
A roundup of news from Canada (Bausch Health), China (Shanghai Pharma), Germany (Biogen), Italy (Angelini), the UK (AstraZeneca), and the US (Gilead Sciences and others).
Canada
Bausch Health To Reduce Debt By $275 M Bausch Health Companies...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from Pfizer, BioNTech, AstraZeneca, Merck & Co., Bayer, Novavax, Regeneron, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
Pfizer,...
As part of ongoing divestment program of non-core assets following its $62-billion acquisition of Shire in 2019, Takeda Pharmaceutical has moved forward with two additional divestment deals totaling a combined $844 million.
In the first deal,...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, reports that the European Commission (EC), Health Canada, the pharmaceutical regulatory body of Canada, and Israel’s Ministry of Health...
Haven Healthcare, a new healthcare company formed by JPMorgan Chase & Co., Berkshire Hathaway, and Amazon in 2018, has announced it will end its independent operations at the end of February (February 2021).
At the time of the forming of the...
